Arkstone Enhances OneChoice with Drug Cost Information: Bringing Transparency to Antimicrobial Prescribing

BOCA RATON, Fla., Feb. 26, 2025 /PRNewswire/ -- Arkstone, the leader in laboratory infectious disease guidance and antimicrobial stewardship, is proud to announce the addition of drug cost information to its OneChoice platform. This new enhancement provides physicians with real-time cost insights on antimicrobial treatments, offering greater financial clarity in prescribing decisions.

Effective antimicrobial prescribing requires a balance of efficacy, safety, and cost considerations. While clinical effectiveness is paramount, the cost of treatment can impact patient adherence and overall healthcare expenses. With the integration of drug cost information, physicians can now access cost insights alongside antimicrobial efficacy and safety data, ensuring that treatment choices are both clinically and financially optimized.

"Adding drug cost information to OneChoice reinforces Arkstone's mission of advancing antimicrobial stewardship and patient-centered care," said Dr. Ari Frenkel, Chief Science Officer at Arkstone. "With rising healthcare costs, physicians need access to transparent drug pricing information. By integrating cost insights directly into OneChoice reports, we ensure that every prescription aligns with both medical efficacy and financial responsibility."

Key Features of the Drug Cost Analysis Tool:

• Transparent Pricing Insights – Provides essential drug cost information to support cost-conscious prescribing.
• Enhanced Decision-Making – Physicians can assess cost data alongside antimicrobial efficacy and safety insights, allowing for a holistic treatment approach.
• Seamless OneChoice Integration – Available directly within OneChoice reports, both in the OneChoice PDF and interactive OneChoice Plus, ensuring a streamlined workflow for clinicians.

"Cost is often an overlooked factor in antimicrobial selection, yet it plays a crucial role in patient adherence and overall healthcare efficiency," added Dave Gross, Chief Technology Officer at Arkstone. "By equipping physicians with real-time cost data, we enable smarter prescribing decisions that benefit both patients and providers."

With the addition of drug cost information, Arkstone continues its commitment to precision-driven antimicrobial stewardship. By equipping clinicians with critical cost insights, Arkstone ensures that every prescription is not only medically sound but also economically responsible—helping healthcare providers make the best treatment choices for both patients and the healthcare system as a whole.

About Arkstone

Arkstone is a global leader in infectious disease clinical guidance and antimicrobial stewardship. Through its AI-enhanced (Antimicrobial Intelligence) solutions, Arkstone provides evidence-based, patient-specific recommendations to combat antibiotic misuse and antimicrobial resistance, ensuring smarter, safer prescribing decisions worldwide.

For more information, visit www.arkstone.ai or contact [email protected].

Media Contact:
Sol Levi
1-833-933-ARK-3
[email protected]

SOURCE Arkstone